# Tectonic Therapeutic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tectonic-therapeutic

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.tectonictx.com/
- Total disclosed funding: $80M
- Latest round: Series A (Mar 31, 2021)
- Investors on record: 3

## About

Tectonic Therapeutic, based in Watertown, US, focuses on the discovery and development of innovative therapeutic proteins and antibodies targeting G-Protein Coupled Receptors (GPCRs) to address significant unmet medical needs.Tectonic Therapeutic, Inc. specializes in creating biologic medicines that target GPCRs, established in 2019 in Watertown, US. The firm has successfully completed four deals, with its most recent funding round occurring on February 2, 2025, where it raised USD 185 mn through PIPE funding involving several prominent investors, including Adage Capital Management and EcoR1 Capital. The CEO of Tectonic is Alise Reicin, who has extensive experience in the biotechnology sector.Tectonic Therapeutic specializes in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors (GPCRs), crucial for many physiological processes. The proprietary GEODe™ platform aids in developing GPCR-targeted biologic medicines that address unmet medical needs, particularly in areas like pulmonary hypertension and hereditary hemorrhagic telangiectasia (HHT). These innovative therapies aim to improve patient quality of life and are primarily marketed to healthcare providers across North America and Europe.Tectonic Therapeutic generates revenue through partnerships and collaborations with other biotechnology and pharmaceutical companies, which include licensing agreements and joint development initiatives. The firm engages in direct sales of its biotech solutions to healthcare providers, streamlining the supply chain for its advanced therapies. The revenue primarily comes from B2B transactions where healthcare organizations purchase Tectonic's biologic therapies, with an achieved EBITDA of USD 10.81 mn in 2023.In February 2025, Tectonic Therapeutic raised approximately USD 185 mn in PIPE funding to support its clinical development initiatives for new products TX45 and TX2100, along with advancements in its discovery platform and general corporate purposes. Tectonic aims to expand its market reach, particularly into new geographic regions in Europe and North America, as it prepares for the upcoming product launches. The recent funding will facilitate these growth strategies and support the pathway towards commercialization.

## Funding rounds

- Series A, Mar 31, 2021, $80M — Polaris Partners, EcoR1 Capital, Vida Ventures
- Seed, Jan 1, 2021 — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A